Loading...

          

50th ASH Annual Meeting & Exposition
Loading...
When Should Patients Be Referred to a Clinical Trial?  »    PDF - 528 kB

Kenneth C. Anderson, MD
Kraft Family Professor of Medicine
Harvard Medical School
Chief, Division of Hematologic Neoplasia
Director, LeBow Institute for Myeloma Therapeutics
Director, Jerome Lipper Center for Multiple Myeloma
Vice Chair, Program in Transfusion Medicine
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts
Should All Patients Who Achieve Complete Response Receive a Transplant?  »    PDF - 254 kB

William Bensinger, MD
Fred Hutchinson Cancer Center
University of Washington
Seattle, Washington
Should All Transplant-Ineligible Patients Receive a Melphalan-Based Induction Regimen?  »    PDF - 257 kB

Sagar Lonial, MD
Associate Professor
Emory University School of Medicine
Director of Translational Research,
B-cell Malignancy Program
The Management of Patients With Relapsed/Refractory Disease: Single-Agent or Combination Therapy?  »   PDF - 324 kB

Paul G. Richardson, MD
Associate Professor of Medicine
Harvard Medical School
Clinical Director, Jerome Lipper Center for Multiple Myeloma
Dana-Farber Cancer Institute
Boston, Massachusetts


Multiple myeloma  »    PDF - 1.629 kB

Robert A. Kyle  and  S. Vincent Rajkumar
Division of Hematology,
Mayo Clinic, Rochester, MN





Bearbeitet von: Dr med. Artur Jurczyszyn

Krakau, ‏18 Dezember 2008



Spendenkonto in PLN  :  06 1440 1127 0000 0000 0835 9709